HAMLET Pharma Announces Results of First Major Clinical Trial for a New Cancer Killing Molecule
Successful clinical trial – Alpha1H shows high efficacy without toxicity Hamlet Pharma is proud to announce the successful outcome of the Phase I/II trial, aimed at studying the safety and efficacy of Alpha1H in patients with bladder cancer. The first data analysis has revealed highly significant differences between the Alpha1H treated patients and the placebo group, for several crucial efficacy variables. Treatment was also shown to be safe, as no drug-related side effects were observed.Alpha1H triggered significant shedding of cells in all tumor patients, who received the treatment (p<